



MAYNE PHARMA APPOINTS LEADER OF USA OPERATIONS

6 September 2013, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has appointed Mr Stefan Cross as President of Mayne Pharma USA, effective from November 2013. Mr Cross will be responsible for leading Mayne Pharma's US business operations which include US Generic Products and Metrics Contract Services, together with other US business development initiatives.

Mr Cross is currently Vice President, Business and Corporate Development and has played a leading role in the commercialisation of SUBACAP® globally. He has also been extensively involved in the integration of Metrics and executing the Company's business strategy both in Australia and the US since he joined the business in 2012.

Mr Cross has more than 20 years of industry experience and was previously the Head of Marketing (Asia Pacific) for Hospira Inc., a leading global provider of pharmaceuticals and medical devices, where he was responsible for the growth of the pharmaceutical and medical devices portfolios across all markets in the region. He also led Hospira's commercial operations in China, Hong Kong and Taiwan. Mr Cross also spent six years with Mayne Pharma Limited in Europe and Australia, and eight years with FH Faulding & Co Limited in various roles.

Mayne Pharma CEO Mr Scott Richards said, "Stefan has an impressive track record of success in the pharmaceutical industry and will add tremendous value to our US business. His breadth of experience covers commercial operations, marketing, product licensing, business strategy and M&A. I look forward to accelerating the growth of our US businesses with Stefan's support and leadership."

"Stefan will succeed Phil Hodges who founded Metrics, Inc. almost two decades ago. Phil will be stepping down as planned from his executive responsibilities at the end of December 2013 but will continue to be a director of Mayne Pharma Group Limited and provide ongoing advice to ensure a smooth leadership transition. I would like to thank Phil for his vision and dedication in developing the Metrics business to where it is today."

For further information contact:

Scott Richards +61 8 8209 2410

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com



ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic product globally - either directly or through distribution partners, while applying its drug delivery expertise for contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, NC, USA with expertise in formulating complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.